Relay Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
60 Hampshire St, Cambridge, Massachusett...Phone Number
(617) 370-8837Website
www.relaytx.comRevenue
$10.7 MillionStock Symbol
RLAYIndustry
ZI Rank: 2
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
2
3
1
1
2
About Relay Therapeutics
Relay Therapeutics is a biotechnology company focused on discovering drugs through protein motion. Founded in 2016 and headquartered in Cambridge, MassachusettsExplore more
Relay Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Relay Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Relay Therapeutics launches new products
Earning: See what the market has to say on Relay Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Relay Therapeutics has new funding data
Relay Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Relay Therapeutics
Click to see if Relay Therapeutics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check if Relay Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Relay Therapeutics is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Relay Therapeutics
Compare insights from companies similar to Relay Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Relay Therapeutics
$10.7M
51-200
Public
$920M
2016
Imogen PryceChief Operating Officer, Research & Development
Company Profile Activity
Activity Insights
Relay Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Relay Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Relay Therapeutics.
Relay Therapeutics financials insights
Gather financial insights about Relay Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$57M
2017
Series B
$63M
2018
Series C
$400M
2020
Stock Offering
$400M
Relay Therapeutics Tech Stack
A closer look at the technologies used by Relay Therapeutics
See more technologies
Most Recent Scoops
Project
intends to engage with the FDA this year regarding the regulatory pathway for accelerated approval of zovegalisib in vascular anomalies, referencing the alpelisib precedent which received approval based on 37 patients from a retrospective chart review as a benchmark, with an anticipated patient enrollment target for accelerated approval falling between 37 and 104 patients.
Pharmaceuticals, Regulations
Event
Events
Person-Based
Events
Person-Based
Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Relay Therapeutics News & Media
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in June:Is Relay Therapeutics a Buy After Promising Trial Results?
Relay Therapeutics, a clinical-stage biotech, is getting a boost after positive trial news for its lead therapy.Relay Therapeutics Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, announced today the pricing of an underwritten public offering of 22,916,667 shares of its common stock at a public offering price of $12.00 per share. Relay Therapeutics also granted the underwriters a 30-day option to purchase up to an additionalWhy Relay Therapeutics Stock Popped on Wednesday
In a way, this was a delayed reaction to excellent news from the lab.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Relay Therapeutics
Sign Up For FreeTo access detailed company insights
Relay Therapeutics is a biotechnology company focused on discovering drugs through protein motion. Founded in 2016 and headquartered in Cambridge, Massachusetts... Read More
